Online citations, reference lists, and bibliographies.
← Back to Search

Neuroexcitatory Amino Acid Levels In Plasma And Cerebrospinal Fluid During Migraine Attacks

F. Martínez, J. Castilló, J. R. Rodríguez, R. Leira, M. Noya
Published 1993 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A current hypothesis for migraine suggests that neuroexcitatory amino acids may participate in the triggering of attacks. To investigate this possibility we measured glutamic and aspartic acid level in plasma and cerebrospinal fluid (CSF) of patients with common and classic migraine during attacks, making comparisons with controls suffering from stress. Plasma levels of amino acids in migraine patients were lower than in controls. CSF concentrations of glutamic acid were higher in migraineurs than in controls. Our results suggest an excess of neuroexcitatory amino acids in the CNS of migraine patients during attacks, possibly favoring a state of neuronal hyperexcitability.
This paper references
Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted?
A. Buchan (1990)
10.1177/03331024870070S634
Tardive Long Lasting Hyperemia In Classic Migraine (Migraine With Aura)
A. Andersen (1987)
10.1001/ARCHNEUR.1985.04060030093015
Is there a difference between classic and common migraine? What is migraine, after all?
D. Dalessio (1985)
10.1038/jcbfm.1990.14
Cortical Spreading Depression is Associated with Arachidonic Acid Accumulation and Preservation of Energy Charge
M. Lauritzen (1990)
10.1038/jcbfm.1989.20
Calcium Fluxes, Calcium Antagonists, and Calcium-Related Pathology in Brain Ischemia, Hypoglycemia, and Spreading Depression: A Unifying Hypothesis
B. Siesjö (1989)
10.1016/0304-3940(85)90290-3
Elevated concentrations of glutamate and aspartate in human ventricular cerebrospinal fluid (vCSF) during episodes of increased CSF pressure and clinical signs of impaired brain circulation
B. Engelsen (1985)
10.1002/NEU.480150504
The nature of the chick's magnesium-sensitive retinal spreading depression
A. V. Harreveld (1984)
10.1016/0896-6273(89)90043-3
Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress
T. Murphy (1989)
10.1111/J.1748-1716.1980.TB06557.X
Relationship between local changes in cortical blood flow and extracellular K+ during spreading depression.
A. Hansen (1980)
Ischemia may be the primary cause of the neurologic deficits in classic migraine.
T. Skyhøj Olsen (1987)
10.1111/j.1526-4610.1976.hed1601024.x
DOUBLE BLIND STUDY OF PROPRANOLOL FOR MIGRAINE PROPHYLAXIS
S. Diamond (1976)
10.1016/S0733-8619(18)30319-0
The concept of migraine as a state of central neuronal hyperexcitability.
K. Welch (1990)
Methods for antagonizing glutamate neurotoxicity.
Choi Dw (1990)
10.1016/0304-3940(89)90217-6
Hypoxia/hypotension evoked release of glutamate and aspartate from the rat cerebral cortex
J. Phillis (1989)
10.1038/271712a0
Chinese Restaurant Syndrome
Liane Reif-Lehrer (1978)
10.1007/978-94-011-3134-6
Neurotransmitters and Drugs
Z. Kruk (1991)
10.1097/00005053-194511000-00029
PROPAGATION OF SPREADING CORTICAL DEPRESSION
A. A. P. Leão (1945)
Glutamate toxicity in a
TH Murphy
10.1152/AJPHEART.1989.257.4.H1200
Dilator effects of amino acid neurotransmitters on piglet pial arterioles.
D. Busija (1989)
10.1002/ANA.410090406
Focal hyperemia followed by spreading oligemia and impaired activation of rcbf in classic migraine
J. Olesen (1981)
10.1212/WNL.40.10.1582
Neuroexcitatory plasma amino acids are elevated in migraine
M. Ferrari (1990)
10.1001/ARCHNEUR.1986.00520100062016
The role of glutamate in neurotransmission and in neurologic disease.
J. T. Greenamyre (1986)
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.
(1988)
10.1001/ARCHNEUR.1985.04060030095016
Common and classic migraine. One or two entities?
V. Hachinski (1985)
10.1021/AC60139A006
Automatic recording apparatus for use in the chromatography of amino acids.
S. Moore (1958)
10.1016/0006-3223(88)90052-2
Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers
G. Alfredsson (1988)
10.1016/0166-2236(87)90115-9
Cortical spreading depression as a putative migraine mechanism
M. Lauritzen (1987)
10.1177/0333102489009S1059
Platelet Excitatory Aminoacids in Migraine
G. D'andrea (1989)
10.1046/j.1468-2982.1988.0804273.x
Brain pH in Migraine: An In Vivo Phosphorus-31 Magnetic Resonance Spectroscopy Study
K. Welch (1988)



This paper is referenced by
10.1007/978-3-319-11870-3_18
The Role of Kynurenine Pathway in Pain and Migraine
Zsófi A. Majláth (2015)
10.2174/1389200217666151222155043
Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism.
N. Török (2016)
Protective compounds in animal models of trigeminal activation and neurodegeneration.
Enikő Vámos (2012)
10.1111/head.12240
Genome‐Wide‐Associated Variants in Migraine Susceptibility: A Replication Study From North India
J. Ghosh (2013)
10.1038/ejhg.2011.48
Meta-analysis of genome-wide association for migraine in six population-based European cohorts
L. Ligthart (2011)
10.5409/wjcp.v4.i1.1
Spectrum of complicated migraine in children: A common profile in aid to clinical diagnosis.
Surya Prakash Gupta (2015)
Neurovascular Pharmacology of Prospective Antimigraine Drugs
K. Chan (2011)
10.1046/j.1468-2982.1996.1601056.x
Cerebrospinal Fluid Tyrosine and 3,4-Dihydroxyphenylacetic Acid Levels in Migraine Patients
J. Castillo (1996)
10.1007/PL00012181
Cortical excitability in migraine
J. Áfra (2000)
10.1186/1744-8069-4-12
Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling
Y. Xiao (2008)
Protective compounds in animal models of trigeminal activation and neurodegeneration
A. Szent-Györgyi (2009)
10.1007/s10194-011-0386-5
Genotype–phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1
A. F. Christensen (2011)
10.1007/978-3-030-14121-9_1
Trigeminal Mechanisms of Nociception
A. Andreou (2020)
10.1517/14656566.8.12.1821
A pharmacogenomic evaluation of migraine therapy
M. P. Johnson (2007)
10.1517/17425255.2014.963554
Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors
J. Tajti (2014)
10.1111/j.1526-4610.2009.01551.x
Capillary Endothelial Na+, K+, ATPase Transporter Homeostasis and a New Theory for Migraine Pathophysiology
M. Harrington (2010)
10.1167/IOVS.06-0393
Transient tritanopia in migraine: evidence for a large-field retinal abnormality in blue-yellow opponent pathways.
M. Tibber (2006)
10.1007/978-3-030-14121-9
Neuromodulation in Headache and Facial Pain Management: Principles, Rationale and Clinical Data
Paolo Martelletti (2020)
10.1046/j.1468-2982.1995.1506489.x
Cerebrospinal Fluid Analyses in Migraine Patients and Controls
J. Rothrock (1995)
10.1161/01.STR.26.11.2035
Amino acid transmitters in patients with headache during the acute phase of cerebrovascular ischemic disease.
J. Castillo (1995)
10.1007/978-1-4020-9838-3_7
Peripheral Biomarkers of Excitotoxicity in Neurological Diseases
L. Tremolizzo (2009)
10.1159/000272024
Evaluation of Plasma Glutamate Levels in Normal Tension Glaucoma
H. Bunting (2009)
10.1016/j.pharmthera.2016.12.005
Current and novel insights into the neurophysiology of migraine and its implications for therapeutics
S. Akerman (2017)
10.1016/0021-9673(95)01170-6
Reference values of neuroactive amino acids in the cerebrospinal fluid by high-performance liquid chromatography with electrochemical and fluorescence detection.
V. Rizzo (1996)
10.1016/J.JPAIN.2004.06.008
Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine.
C. Ghelardini (2004)
10.1007/s13361-015-1136-8
Large-Scale Mass Spectrometry Imaging Investigation of Consequences of Cortical Spreading Depression in a Transgenic Mouse Model of Migraine
Ricardo J. Carreira (2015)
10.1027//0269-8803.15.1.22
Visual spatial attention in migraine sufferers in postictal and interictal phases: An event-related potential study.
D. Koning (2001)
10.1111/j.1526-4610.2006.00525.x
Selected Confirmed, Probable, and Exploratory Migraine Biomarkers
E. Loder (2006)
10.1007/s00702-011-0665-y
Kynurenines and headache
Á. Párdutz (2011)
Identification of Migraine Susceptibility Genes: Candidate Gene Studies
C. Gasparini (2014)
10.1111/J.1743-5013.2005.00017.X
Cortical Spreading Depression: A Model for Understanding Migraine Biology and Future Drug Targets
K. Haerter (2005)
10.1177/0333102411418259
Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway
A. Andreou (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar